Phathom Pharmaceuticals, Inc. Debt/Assets

Debt/Assets of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Assets growth rates and interactive chart.

Highlights and Quick Summary

  • Debt/Assets for the quarter ending September 29, 2021 was 39.44% (a 70.81% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Assets increased by 137.45%
  • Annual Debt/Assets for 2020 was 16.61% (a 81.13% increase from previous year)
  • Annual Debt/Assets for 2019 was 9.17% (a -95.76% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Assets of Phathom Pharmaceuticals, Inc.

Most recent Debt/Assetsof PHAT including historical data for past 10 years.

Interactive Chart of Debt/Assets of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Debt/Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 39.44% 23.09% 20.01%
2020 16.61% 21.09% 18.33% 17.45% 16.61%
2019 8.92% 147.84% 0.0% 0.0% 9.17%
2018 0.0% 0.0% 216.19%

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.